MTOR and cancer: Screening of 247 anti-cancer compounds, targeting a wide range of pathways including angiogenesis, apoptosis, PI3K/AKT/mTOR, MAPK, protein tyrosine kinases and metabolism, was performed on MDA-MB-231 cells to identify NCK-based synergistic combinations in TNBC cells (Fig. 5a).